gptkbp:instance_of
|
gptkb:fragrance
|
gptkbp:activities
|
factor Xa inhibitor
|
gptkbp:appointed_by
|
oral tablet
|
gptkbp:approves
|
gptkb:2012
gptkb:FDA
|
gptkbp:brand
|
gptkb:Eliquis
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:contraindication
|
active bleeding
severe renal impairment
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
hypersensitivity to apixaban
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
gptkbp:dosage_form
|
5 mg tablet
2.5 mg tablet
|
gptkbp:excretion
|
kidneys
|
https://www.w3.org/2000/01/rdf-schema#label
|
apixaban
|
gptkbp:interacts_with
|
gptkb:HIV_protease_inhibitors
certain antibiotics
antiplatelet agents
other anticoagulants
certain antifungals
|
gptkbp:is_available_in
|
many countries
|
gptkbp:is_available_on
|
generic version
|
gptkbp:is_monitored_by
|
renal function
liver function
|
gptkbp:is_used_for
|
preventing blood clots
reducing the risk of stroke
treating deep vein thrombosis
treating pulmonary embolism
|
gptkbp:lifespan
|
8 to 15 hours
|
gptkbp:marketed_as
|
anticoagulant therapy
|
gptkbp:metabolism
|
liver
|
gptkbp:side_effect
|
nausea
bruising
bleeding
|
gptkbp:suitable_for
|
pregnancy
breastfeeding
|
gptkbp:used_in
|
gptkb:atrial_fibrillation
venous thromboembolism
|
gptkbp:bfsParent
|
gptkb:deep_vein_thrombosis
gptkb:Eliquis
|
gptkbp:bfsLayer
|
4
|